OOIR: Observatory of International Research

Papers

(The TQCC of Drugs is 25. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-12-01 to 2025-12-01.)

Article	Citations
Correction: Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments	466
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression	390
Suprachoroidal Space Triamcinolone Acetonide: A Review in Uveitic Macular Edema	241
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences	213
Senaparib: First Approval	199
Targeting DNA Damage Response Deficiency in Thoracic Cancers	191
Eftrenonacog Alfa: A Review in Haemophilia B	179
Comment on “Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study”	149
Aztreonam-Avibactam: A Review in the Treatment of Serious Bacterial Infections Caused by Aerobic Gram-Negative Organisms	147
Authors’ Reply to Toda: Multimodal Multidisciplinary Management of Patients with Moderate to Severe Pain in Knee Osteoarthritis: A Need to Meet Patient Expectations	143
Epcoritamab: First Approval	140
Acknowledgement to Referees	130
Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using	128
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments	126
Vorasidenib: First Approval	124
Teclistamab: First Approval	116
Aprocitentan: First Approval	113
New Therapies on the Horizon for Primary Biliary Cholangitis	107
Spesolimab for the Treatment of Generalized Pustular Psoriasis	107
Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEε4/ε4 Homozygotes with Early Alzheimer’s Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled,	106
Efficacy and Safety of Plecanatide in Chinese Patients with Functional Constipation: A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial	105
Ivarmacitinib Sulfate: First Approval	103
QT Prolongation and Risk of Death with the Use of Methadone for Chronic Cancer and Noncancer Pain: Myths or Reality?	99
Acoltremon: First Approval	97
Drugs in Development to Manage Acute Pain	95

Cosibelimab: First Approval	89
Repotrectinib: First Approval	88
Olipudase Alfa: First Approval	87
Danicopan: First Approval	87
Safety of Anti-osteoarthritis Medications: A Systematic Literature Review of Post-marketing Surveillance Studies	85
Lenacapavir: First Approval	85
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine	83
Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure	83
Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer	82
Advances in Pharmacotherapy for Menopausal Vasomotor Symptoms	81
Tolebrutinib: First Approval	79
Androgenetic Alopecia: Therapy Update	79
Correction to: Ofatumumab: A Review in Relapsing Forms of Multiple Sclerosis	78
Delgocitinib 20 mg/g Cream: A Review in Chronic Hand Eczema	77
Mosunetuzumab: First Approval	70
SER-109 (VOWST™): A Review in the Prevention of Recurrent Clostridioides difficile Infection	70
Treatment of Cryptococcal Meningitis: How Have We Got Here and Where are We Going?	67
Mazdutide: First Approval	67
Olverembatinib: First Approval	67
Cancer Pain Treatment Strategies in Patients with Cancer	65
Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids	65
Alzheimer’s Disease: Novel Targets and Investigational Drugs for Disease Modification	65
Novel Drugs for the Treatment of Pulmonary Arterial Hypertension: Where Are We Going?	63
Managing Burning Mouth Syndrome: Current and Future Directions	62
Situational Prevention of Migraine Attacks: Can Early Treatment Change the Conversation?	60
Correction to: Tapinarof Cream 1%: First Approval	59
Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes	59
Drugs Targeting Cough Receptors: New Therapeutic Options in Refractory or Unexplained Chronic Cough	59
Correction to: Prevention and Treatment of Monkeypox	59
Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned	58
Aligning Large Language Models with Humans: A Comprehensive Survey of ChatGPT’s Aptitude in Pharmacology	58
The Place of Cannabinoids in the Treatment of Gynecological Pain	58
PARP Inhibition, a New Therapeutic Avenue in Patients with Prostate Cancer	57
Pozelimab: First Approval	57
Treatment of Ovarian Cancer Beyond PARP Inhibition: Current and Future Options	57
Ifupinostat: First Approval	54
Taletrectinib: First Approval	53
Tovorafenib: First Approval	52
Sunvozertinib: First Approval	52
Dorzagliatin: First Approval	51
Pharmacological Treatments of Temporomandibular Disorders: A Systematic Review Including a Network Meta-Analysis	51
Correction to: Concizumab: First Approval	50
Recent Human Papillomavirus Vaccination is Associated with a Lower Risk of COVID-19: A US Database Cohort Study	49
Targeting HER2 in Metastatic Colorectal Cancer: Current Therapies, Biomarker Refinement, and Emerging Strategies	49
Birch Bark Extract: A Review in Epidermolysis Bullosa	48
Might It Be Appropriate to Anticipate the Use of Long-Acting Muscarinic Antagonists in Asthma?	48
The Utilization of the Accelerated Approval Pathway in Oncology: A Case Study of Pembrolizumab	47
Correction to: Remdesivir: A Review in COVID-19	45
Correction: From Prospective Evaluation to Practice: Model-Informed Dose Optimization in Oncology	44
Paracetamol Combination Therapy for Back Pain and Osteoarthritis: A Systematic Review and Meta-Analyses	44

Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence	44
Catumaxomab: First Approval	43
Focus on Metformin: Its Role and Safety in Pregnancy and Beyond	43
Asciminib: First Approval	42
Ozoralizumab: First Approval	41
Gepirone Extended-Release: First Approval	41
Pan-JAK Inhibition Across Chronic Hand Eczema and Other Cutaneous Diseases: An Updated Review on Topical Delgocitinib	41
Givinostat: First Approval	41
Tirzepatide: A Review in Type 2 Diabetes	40
Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy	40
Correction to: Efmoroctocog Alfa: A Review in Haemophilia A	39
Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’	39
Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials	39
Aumolertinib: A Review in Non-Small Cell Lung Cancer	39
Correction: Teprotumumab: A Review in Thyroid Eye Disease	38
Current and Emerging Treatments for Acid Sphingomyelinase Deficiency	38
Update on Mpox Management: Epidemiology, Vaccines and Therapeutics, and Regulatory Changes	37
Fezolinetant: First Approval	37
Mitapivat: A Review in Pyruvate Kinase Deficiency in Adults	37
Avacincaptad Pegol: First Approval	36
Treatment of Non-Infectious Corneal Injury: Review of Diagnostic Agents, Therapeutic Medications, and Future Targets	36
Omalizumab in Severe Asthma: Effect on Oral Corticosteroid Exposure and Remodeling. A Randomized Open-Label Parallel Study	35
Futibatinib: First Approval	35
Atrasentan: First Approval	35
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials	34
Current Understanding of Complement Proteins as Therapeutic Targets for the Treatment of Immunoglobulin A Nephropathy	34
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 1	34
Advanced-Stage Chronic Myeloid Leukemia: Options for Difficult Treatment Situations	34
Imetelstat: First Approval	34
Ensitrelvir Fumaric Acid: First Approval	34
Zastaprazan: First Approval	33
Correction: Iptacopan: First Approval	33
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?	33
Spondyloarthropathy in Inflammatory Bowel Disease: From Pathophysiology to Pharmacological Targets	32
Managing Pain in Fibromyalgia: Current and Future Options	32
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis	32
Gastrointestinal Dysfunction in Parkinson’s Disease	32
Eye Involvement and Management in Inherited Epidermolysis Bullosa	32
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease	31
Beremagene Geperpavec: First Approval	31
Lotilaner Ophthalmic Solution 0.25%: First Approval	31
Varenicline Solution Nasal Spray: A Review in Dry Eye Disease	31
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases	31
Acknowledgement to Referees	30
Remdesivir Discontinuation Decisions Based on Thresholds of Aminotransferase in an Observational Registry	30
Tebentafusp: First Approval	30
Correction to: Pharmacological Approaches to Managing Violence and Aggression in Prison Populations: Clinical and Ethical Issues	30
Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries	30
Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”	30
Mavorixafor: First Approval	29
Nogapendekin alfa Inbakicept: First Approval	29
Sepiapterin: First Approval	29
Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management	29
Efficiency and Safety of Noninvasive and Intravesical Therapy for Adult Neurogenic Lower Urinary Tract Dysfunction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials	29
Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes	28
Diagnosis and Treatment of AL Amyloidosis	28
Crinecerfont: First Approval	28
Revumenib: First Approval	28
Botulinum Toxin-A for the Treatment of Myogenous Temporomandibular Disorders: An Umbrella Review of Systematic Reviews	27
Revolutionary Changes in the Management of Lupus Nephritis: Towards De-Glucocorticoid or No-Glucocorticoid	27
Retifanlimab: First Approval	27
Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy	26
Zolbetuximab: First Approval	26
Correction to: Sparsentan: First Approval	26
Correction to: Spesolimab: First Approval	26
Direct-Acting Antivirals and the Risk of Arrhythmias and Conduction Disorders in Patients with Chronic Hepatitis C: A French Nationwide Cohort Study	26
Correction to: Abrocitinib: First Approval	26
Onradivir: First Approval	26
Gabapentinoids for Pain: A Review of Published Comparative Effectiveness Trials and Data Submitted to the FDA for Approval	26
Correction: Zastaprazan: First Approval	26
Efficacy and Safety of Sovateltide in Patients with Acute Cerebral Ischaemic Stroke: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase III Clinical Trial	25
Ravulizumab: A Review in Generalised Myasthenia Gravis	25
Moderate-Intensity Statin Plus Ezetimibe: Time to Rethink it as an Optimal Initial Lipid-Lowering Strategy	25
Keverprazan Hydrochloride: First Approval	25
Daridorexant: First Approval	25
Remdesivir: A Review in COVID-19	25
Comment on: “Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study”	25
Combination of PARP Inhibitors and Androgen Receptor Pathway Inhibitors in Metastatic Castration-Resistant Prostate Cancer	25
Methadone for Cancer Pain Management in Children: A Review of Literature	25